Delving into the Latest Updates on PATH Corp. with Synapse

概览

关联

1

项与 PATH Corp. 相关的药物

Recombinant ETEC CssBA protein(PATH Corp.)

靶点-

作用机制-

在研机构-

原研机构

Program for Appropriate Technology in Health

在研适应症-

非在研适应症

腹泻

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

27

项与 PATH Corp. 相关的临床试验

NCT06895486

/ Not yet recruiting临床2期

A Phase 2, Randomized, Double- Dummy, Observer-Blind Study to Evaluate the Safety and Immunogenicity of Co-administered Novel Live Attenuated Monovalent Oral Poliomyelitis Vaccines in Healthy Young Infants Relative to Monovalent Vaccines Alone in Panama.

The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to corresponding doses of nOPV1 alone and nOPV2 alone.

开始日期2025-09-29

申办/合作机构

PATH Corp.

[+3]

ISRCTN15552312

/ RecruitingN/A

A mixed-method operational research study on the use of tafenoquine and G6PD testing for radical cure of Plasmodium vivax malaria in passive and active case detection in Vietnam

开始日期2025-04-15

申办/合作机构

PATH Corp.

NCT06879327

/ Not yet recruiting临床2期

A Phase 2b Multicenter Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate the Safety, Immunogenicity and Efficacy of R21/Matrix-M Malaria Vaccine in African Infants With Different Immunization Schedules

The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.

开始日期2025-04-02

申办/合作机构

PATH Corp.

[+5]

100 项与 PATH Corp. 相关的临床结果

登录后查看更多信息

0 项与 PATH Corp. 相关的专利（医药）

登录后查看更多信息

100 项与 PATH Corp. 相关的药物交易

登录后查看更多信息

100 项与 PATH Corp. 相关的转化医学

登录后查看更多信息